PRP Arthritis Clinic of Toronto 89 Humber College Boulevard Suite 315 Toronto ON M9V 4B8 CA
|
PRP Toronto

Welcome to PRP Toronto and the home of arthritis treatment

Dedicate yourself to a higher quality of life!

WHAT IS PLATELET-RICH PLASMA (PRP)?

Blood is mainly a liquid, but contains small solid components. These components are suspended in a liquid called plasma, and are comprised of red cells, white cells and platelets. This is the key to relieving the arthritis in knee.


Typically a blood specimen contains 93% red cells, 1% white cells and 6% platelets. Each component plays an important role for the human body to function. Red blood cells serve to carry oxygen from the lungs and to deliver it to other cells throughout the body, while also removing carbon dioxide. White blood cells fight infection, kill germs, and carry off dead blood cells. Platelets are responsible for the construction of new connective tissue, and contain proteins called growth factors that are very important in the healing of injuries, and serves as an arthritis treatment. Simply put, PRP is plasma that has been modified to have a higher concentration of platelets.


THE EFFICACY OF PLATELET-RICH PLASMA IN THE TREATMENT OF SYMPTOMATIC KNEE OSTEOARTHRITIS:

A SYSTEMATIC REVIEW WITH QUANTITATIVE SYNTHESIS


Amir Khoshbin, M.D., Timothy Leroux, M.D., David Wasserstein, M.D., M.Sc., F.R.C.S.C., Paul Marks, M.D., F.R.C.S.C., John Theodoropoulos, M.D., M.Sc., F.R.C.S.C., Darrell Ogilvie-Harris, M.D., F.R.C.S.C., Rajiv Gandhi, M.D., F.R.C.S.C., Kirat Takhar, B.Kin., Grant Lum, M.D., Jaskarndip Chahal, M.D., M.Sc., F.R.C.S.C.


Purpose


The purpose of this systematic review was to synthesize the available Level I and Level II literature on platelet-rich plasma (PRP) as a therapeutic intervention in the management of symptomatic knee osteoarthritis (OA).


Methods


A systematic review of Medline, Embase, Cochrane Central Register of Controlled Trials, PubMed, andwww.clinicaltrials.gov was performed to identify all randomized controlled trials and prospective cohort studies that evaluated the clinical efficacy of PRP versus a control injection for knee OA. A random-effects model was used to evaluate the therapeutic effect of PRP at 24 weeks by use of validated outcome measures (Western Ontario and McMaster Universities Arthritis Index, visual analog scale for pain, International Knee Documentation Committee Subjective Knee Evaluation Form, and overall patient satisfaction).


​Results


Six Level I and II studies satisfied our inclusion criteria (4 randomized controlled trials and 2 prospective nonrandomized studies). A total of 577 patients were included, with 264 patients (45.8%) in the treatment group (PRP) and 313 patients (54.2%) in the control group (hyaluronic acid [HA] or normal saline solution [NS]). The mean age of patients receiving PRP was 56.1 years (51.5% male patients) compared with 57.1 years (49.5% male patients) for the group receiving HA or NS. Pooled results using the Western Ontario and McMaster Universities Arthritis Index scale (4 studies) showed that PRP was significantly better than HA or NS injections (mean difference, −18.0 [95% confidence interval, −28.8 to −8.3]; P< .001). Similarly, the International Knee Documentation Committee scores (3 studies) favored PRP as a treatment modality (mean difference, 7.9 [95% confidence interval, 3.7 to 12.1]; P < .001). There was no difference in the pooled results for visual analog scale score or overall patient satisfaction. Adverse events occurred more frequently in patients treated with PRP than in those treated with HA/placebo (8.4% v 3.8%, P = .002).


Conclusions


As compared with HA or NS injection, multiple sequential intra-articular PRP injections may have beneficial effects in the treatment of adult patients with mild to moderate knee OA at approximately 6 months. There appears to be an increased incidence of nonspecific adverse events among patients treated with PRP.


Level of evidence


Level II, systematic review of Level I and II studies.

Subscribe

Sign up to hear from us.